LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

Home・Listă Acțiuni・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Închisă

SectorSănătate

68.2 2.6

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

65.62

Maxim

68.8

Indicatori cheie
By Trading Economics
Venit	292M 150M
Vânzări	-75M 377M
P/E Medie Sector	24.112 50.102
EPS	1.221
Marjă de profit	39.832
Angajați	423
EBITDA	-63M 218M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+25.92% upside

Dividende
By Dow Jones
Următoarele câștiguri	4 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	501M 8.2B
Deschiderea anterioară	65.6
Închiderea anterioară	68.2

Sentimentul știrilor

By Acuity

13%

87%

15 / 344 Clasament în Healthcare

Halozyme Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

1 iun. 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 iun. 2026, 23:38 UTC

Achiziții, Fuziuni, Preluări

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 iun. 2026, 23:37 UTC

Market Talk

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 iun. 2026, 23:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 iun. 2026, 23:01 UTC

Market Talk

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 iun. 2026, 22:08 UTC

Achiziții, Fuziuni, Preluări

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 iun. 2026, 22:01 UTC

Achiziții, Fuziuni, Preluări

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 iun. 2026, 22:01 UTC

Achiziții, Fuziuni, Preluări

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 iun. 2026, 21:55 UTC

Achiziții, Fuziuni, Preluări

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 iun. 2026, 21:53 UTC

Market Talk

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 iun. 2026, 21:22 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 iun. 2026, 20:50 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Tech, Media & Telecom Roundup: Market Talk

1 iun. 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 iun. 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

1 iun. 2026, 20:46 UTC

Achiziții, Fuziuni, Preluări

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 iun. 2026, 20:22 UTC

Achiziții, Fuziuni, Preluări

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 iun. 2026, 20:21 UTC

Achiziții, Fuziuni, Preluări

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 iun. 2026, 20:21 UTC

Achiziții, Fuziuni, Preluări

Array Digital Infrastructure Declares $11 Special Div

1 iun. 2026, 20:20 UTC

Achiziții, Fuziuni, Preluări

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 iun. 2026, 19:40 UTC

Market Talk

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 iun. 2026, 19:28 UTC

Market Talk

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 iun. 2026, 19:01 UTC

Market Talk

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 iun. 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 iun. 2026, 18:54 UTC

Achiziții, Fuziuni, Preluări

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 iun. 2026, 18:33 UTC

Market Talk

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 iun. 2026, 18:32 UTC

Market Talk

Precious Metals Fall to Start June -- Market Talk

1 iun. 2026, 18:00 UTC

Achiziții, Fuziuni, Preluări

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 iun. 2026, 17:18 UTC

Market Talk

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 iun. 2026, 17:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 iun. 2026, 17:10 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Comparație

Modificare preț

Halozyme Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

25.92% sus

Prognoză pe 12 luni

Medie 85.8 USD 25.92%

Maxim 96 USD

Minim 70 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruHalozyme Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

5 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 5 analiști care au acordat evaluări ale acțiunilor Halozyme Therapeutics Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

15 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.